정맥내 수액 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the intravenous solutions market size was valued at USD 13.58 billion in 2025 and estimated to grow from USD 14.27 billion in 2026 to reach USD 18.28 billion by 2031, at a CAGR of 5.08% during the forecast period (2026-2031).

This report is Segmented by Type (Total Parenteral Nutrition, Peripheral Parenteral Nutrition), Solution Composition (Saline, Carbohydrates, and More), Packaging Material (Glass Bottles, PVC Plastic Bags, and More), End User (Hospitals & Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Intravenous Solutions Market Trends and Insights

Adoption of AI-Enabled, Personalized Parenteral Nutrition Protocols

AI-driven software now matches expert TPN orders with 94% concordance, while cutting dosing-error rates by 54%. Hospitals processing tens of thousands of nutrition prescriptions annually save minutes per preparation, freeing pharmacy labor and lowering cost. Standardized yet individualized regimens enhance evidence-based compliance and safeguard metabolic outcomes across neonatal and adult ICUs. Scalability makes the approach attractive for resource-limited centers that lack full-time nutritionists. Consequently, clinical protocols are shifting from manual calculations toward algorithm-guided prescriptions, reinforcing demand for formulation flexibility in the intravenous solutions market.

Steady Rise in Chronic Disease Prevalence

In 2024, 76.4% of US adults reported at least one chronic ailment, driving recurrent hospitalizations that depend on parenteral hydration and nutrition. Younger patients increasingly present with multimorbidity, extending lifetime exposure to IV therapy. Surgeons anticipate thoracolumbar fusion procedures to rise to 297,994 cases by 2040, creating larger perioperative fluid needs. Hospitals therefore favor broad-spectrum IV platforms capable of supporting multi-drug regimens, a trend that reinforces baseline growth in the intravenous solutions market.

High Compliance Burden Associated With GMP

Revised EU Annex 1 now requires full contamination-control strategies and extensive barrier technology, raising capital thresholds for smaller firms. Validation of ready-to-use containers prolongs launch timelines by as much as 18 months, and documentation can consume 20% of development budgets. In emerging regions, diverging national rules oblige parallel audits, draining regulatory resources. These burdens deter new entrants and limit price competition, moderating growth in the intravenous solutions market.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Growth of Home-Based and Ambulatory Care Models
2. Ageing Population Coupled with Increased Surgical Volumes
3. Ongoing Supply-Chain Constraints

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Total parenteral nutrition generated the largest revenue, equal to 61.72% of intravenous solutions market share in 2025. AI-guided calculators now tailor amino-acid, lipid, and electrolyte loads to metabolic markers, transforming TPN into a precision tool rather than a static recipe. Demand remains entrenched in neonatal and oncologic wards where gut function is compromised.

Peripheral Parenteral Nutrition, although accounting for a smaller base, is forecast to post the leading 8.26% CAGR. Home infusion programs favor PPN because peripheral lines avoid central-catheter infection risk and simplify nursing care. Multi-chamber PPN bags cut compounding errors, and stability-enhanced formulations extend hang times, supporting out-of-hospital uptake. The result is a steady re-balancing of volumes inside the intravenous solutions market as clinicians weigh risk, cost, and patient comfort.

Saline maintained a 52.60% revenue share in 2025, underscoring its ubiquity in resuscitation and dilution tasks. Nevertheless, omega-3 enriched lipid emulsions are advancing at 9.02% CAGR between 2026 and 2031. Composite products such as SMOFlipid curb hepatotoxicity and modulate inflammation, creating measurable survival benefits in ICU cohorts.

Protein hydrolysates, carbohydrate blends, and trace-element cocktails enjoy niche growth as evidence supports tighter nutrient control during sepsis and trauma recovery. Research into heat-stable protein carriers that remain bioactive after pasteurization may soon eliminate cold-chain dependence, opening frontier markets and reinforcing geographical diversity of the intravenous solutions market.

Complete Report Scope:

• By Type
  • Total Parenteral Nutrition (TPN)
  • Peripheral Parenteral Nutrition (PPN)
• By Solution Composition
  • Saline
  • Carbohydrates
  • Amino-acid & Protein Hydrolysates
  • Lipid Emulsions
  • Electrolytes, Vitamins & Trace Elements
• By Packaging Material
  • Glass Bottles
  • PVC Plastic Bags
  • Non-PVC/Polyolefin Bags
• By End User
  • Hospitals & Clinics
  • Ambulatory Surgery & Infusion Centres
  • Home-Care Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained the largest regional stake with 39.35% of 2025 revenue, backed by advanced hospital networks and early uptake of AI dosing software. Executive Order 14293 and parallel state incentives are now underwriting new sterile-fill facilities in the Midwest, dispersing risk away from hurricane-prone regions. High insurance penetration also supports premium pricing for innovative non-PVC bags, further boosting the region's intravenous solutions market performance.

Asia-Pacific displays the strongest momentum with a forecast 6.93% CAGR through 2031. China's provincial tenders favor local capacity additions, while India leverages low-cost fill-finish labor for export contracts. Japan channels R&D subsidies into emulsions enriched with long-chain fatty acids that meet stringent geriatrics guidelines. Rising prevalence of diabetes and obesity in Southeast Asia likewise elevates demand for electrolyte-controlled solutions, making the region a critical growth engine for the intravenous solutions market.

Europe shows steady expansion anchored in stringent quality rules that reward GMP compliance. Hospitals prioritize DEHP-free sourcing, accelerating non-PVC conversion and opening premium niches. Meanwhile, Eastern European contract manufacturers bid for supplemental production to backstop Western shortages. Collectively, these dynamics keep the intravenous solutions industry resilient despite environmental taxes and evolving pharmacopoeia standards.

1. Baxter
2. B. Braun
3. Fresenius
4. Grifols
5. ICU Medical
6. Ajinomoto Co., Inc.
7. Otsuka
8. PHARMASYNTEZ JSC
9. SGD Pharma
10. Vifor Pharma Ltd.
11. Hospira Inc. (Pfizer)
12. JW Life Science Co., Ltd.
13. Sichuan Kelun Pharmaceutical
14. Terumo
15. Aculife Healthcare Pvt. Ltd.
16. SSY Group Limited
17. Nipro
18. Axa Parenterals Ltd.
19. JMS Co., Ltd.
20. Qilu Pharmaceutical Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Adoption of AI-Enabled, Personalized Parenteral Nutrition Protocols
  • 4.2.2 Steady Rise in Chronic Disease Prevalence
  • 4.2.3 Rapid Growth of Home-Based and Ambulatory Care Models
  • 4.2.4 Ageing Global Population Coupled with Increased Surgical Intervention Volumes
  • 4.2.5 Emergence of Stability-Optimized Large-Volume Parenterals
  • 4.2.6 Government-Backed Onshoring Initiatives
• 4.3 Market Restraints
  • 4.3.1 High Compliance Burden Associated With GMP
  • 4.3.2 Ongoing Supply Chain Constraints
  • 4.3.3 Environmental Scrutiny of Single-Use IV Plastics
  • 4.3.4 Clinical Shift Toward Subcutaneous and Enteral Administration Routes
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitutes
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Type
  • 5.1.1 Total Parenteral Nutrition (TPN)
  • 5.1.2 Peripheral Parenteral Nutrition (PPN)
• 5.2 By Solution Composition
  • 5.2.1 Saline
  • 5.2.2 Carbohydrates
  • 5.2.3 Amino-acid & Protein Hydrolysates
  • 5.2.4 Lipid Emulsions
  • 5.2.5 Electrolytes, Vitamins & Trace Elements
• 5.3 By Packaging Material
  • 5.3.1 Glass Bottles
  • 5.3.2 PVC Plastic Bags
  • 5.3.3 Non-PVC/Polyolefin Bags
• 5.4 By End User
  • 5.4.1 Hospitals & Clinics
  • 5.4.2 Ambulatory Surgery & Infusion Centres
  • 5.4.3 Home-Care Settings
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Baxter International Inc.
  • 6.3.2 B. Braun SE
  • 6.3.3 Fresenius Kabi AG
  • 6.3.4 Grifols S.A.
  • 6.3.5 ICU Medical Inc.
  • 6.3.6 Ajinomoto Co., Inc.
  • 6.3.7 Otsuka Pharmaceutical Co., Ltd.
  • 6.3.8 PHARMASYNTEZ JSC
  • 6.3.9 SGD Pharma
  • 6.3.10 Vifor Pharma Ltd.
  • 6.3.11 Hospira Inc. (Pfizer)
  • 6.3.12 JW Life Science Co., Ltd.
  • 6.3.13 Sichuan Kelun Pharmaceutical Co., Ltd.
  • 6.3.14 Terumo Corporation
  • 6.3.15 Aculife Healthcare Pvt. Ltd.
  • 6.3.16 SSY Group Limited
  • 6.3.17 Nipro Corporation
  • 6.3.18 Axa Parenterals Ltd.
  • 6.3.19 JMS Co., Ltd.
  • 6.3.20 Qilu Pharmaceutical Co., Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment